U.S. markets open in 5 hours 17 minutes

  • S&P Futures

    4,717.00
    +15.50 (+0.33%)
     

  • Dow Futures

    35,907.00
    +96.00 (+0.27%)
     

  • Nasdaq Futures

    16,565.00
    +83.75 (+0.51%)
     

  • Russell 2000 Futures

    2,371.30
    +7.10 (+0.30%)
     

  • Crude Oil

    79.37
    +0.36 (+0.46%)
     

  • Gold

    1,854.80
    -6.60 (-0.35%)
     

  • Silver

    24.80
    -0.10 (-0.40%)
     

  • EUR/USD

    1.1325
    -0.0050 (-0.44%)
     

  • 10-Yr Bond

    1.5890
    0.0000 (0.00%)
     

  • Vix

    17.31
    +0.20 (+1.17%)
     

  • GBP/USD

    1.3451
    -0.0049 (-0.36%)
     

  • USD/JPY

    114.4920
    +0.2400 (+0.21%)
     

  • BTC-USD

    57,165.06
    -2,280.00 (-3.84%)
     

  • CMC Crypto 200

    1,414.96
    -52.97 (-3.61%)
     

  • FTSE 100

    7,283.21
    +27.25 (+0.38%)
     

  • Nikkei 225

    29,745.87
    +147.21 (+0.50%)
     

Financial Calendar 2022

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
ORPHAZYME A/S
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Orphazyme A/S
Company announcement

No. 26/2021
www.orphazyme.com
Company Registration No. 32266355


Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to the following schedule:


Deadline for submission of shareholder proposals to Annual General Meeting
February 23, 2022

Annual Report 2021
March 15, 2022

Annual General Meeting 2022
April 7, 2022

Interim Report First Half 2022
August 25, 2022

The financial reports will upon their release be available at the Company's website, www.orphazyme.com, where information relating to Orphazyme's Annual General Meeting 2022 will also be available in due course prior to the meeting.


For additional information, please contact:

Orphazyme A/S

Anders Vadsholt, Chief Financial Officer +45 2898 9055


About Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. ADSs representing Orphazyme’s shares are listed on The Nasdaq Global Select Market (ORPH) and its shares are listed on Nasdaq Copenhagen (ORPHA).

Attachment


Recommended Stories

  • Insurers run from ransomware cover as losses mount

    Insurers have halved the amount of cyber cover they provide to customers after the pandemic and home-working drove a surge in ransomware attacks that left them smarting from hefty payouts. Faced with increased demand, major European and U.S. insurers and syndicates operating in the Lloyd's of London market have been able to charge higher premium rates to cover ransoms, the repair of hacked networks, business interruption losses and even PR fees to mend reputational damage. But the increase in ransomware attacks and the growing sophistication of attackers have made insurers wary.

  • Leisure Travel Big Opportunity as Borders Open: Ling

    Ling Hai, co-president for APAC at Mastercard Inc., discusses expanding into the crypto industry, growth markets in Asia and how the business will be impacted once economies reopen after the pandemic. He speaks on "Bloomberg Markets: Asia" from the sidelines of the 4th annual Bloomberg New Economy Forum in Singapore.

  • As dual listings fall out of favour, Rio Tinto set to hold the line

    Global miner Rio Tinto Ltd has no plans to follow in the footsteps of peers BHP and Shell to collapse its dual listing, people familiar with its thinking say, seeing it as a needless expense that would erode advantages for shareholders in London and Sydney. Executives at Rio routinely review the dual structure and have for years resisted any change, a direction unlikely to shift under the helm of new chief executive Jakob Stausholm, two sources familiar with the company told Reuters. Just last month, Stausholm defended the dual listing as an effective one-management, one-board structure set up 26 years ago to satisfy both the UK and Australian governments that he thought management should "honour."

  • Warren Buffett Wishes He Owned A Whole Lot More Of These 6 Stocks

    When more than half Warren Buffett stocks lag the S&P 500 this year — you wish you owned a whole lot more of the winners.

  • Why General Electric Stock Dropped Today

    Shares of industrial giant General Electric (NYSE: GE) -- which is soon to be three industrial giants -- closed Thursday's session down by 1.3%. You can thank JP Morgan for that. In a note out Thursday morning, JP Morgan analyst Stephen Tusa warned that there's a "mechanical flaw" in the valuations that other analysts have been positing for GE stock in the wake of the conglomerate's decision to divide itself into three independent companies.

  • Tesla Stock Price Target Hiked To Street High As House Eyes New EV Credits

    Wedbush analyst Dan Ives raised his Tesla price target to $1,400 from $1,000 as a House vote neared on legislation with EV credits.

  • Alibaba sinks, Kohl's beats, Ford and GM get into the chipmaking game

    Yahoo Finance's Ines Ferre details some stocks on the move in midday trading.

  • Why Shares of StoneCo Crashed This Week

    Shares of the Brazilian fintech company StoneCo (NASDAQ: STNE) plummeted more than 36% this week, as of market close Thursday, after StoneCo reported earnings results for the third quarter of 2021 that were not well received by the market. StoneCo reported a net loss equivalent to $230 million on total revenue equivalent to roughly $270 million. On an adjusted basis, StoneCo reported the equivalent of a roughly $24 million profit, which missed analyst expectations for adjusted net income.

  • 10 Dividend Stocks in Warren Buffett’s Latest Portfolio

    In this article, we discuss the 10 dividend stocks in Warren Buffett’s latest portfolio. If you want to skip our detailed analysis of these stocks, go directly to the 5 Dividend Stocks in Warren Buffett’s Latest Portfolio. Warren Buffett, the Omaha-born chief of Berkshire Hathaway, has become a global brand over the years due to […]

  • Billionaire Ray Dalio: 'Misery and turbulence' ahead after inflation hits 31-year high — here are 3 shockproof stocks he's leaning on now

    'The king of hedge funds' says the US is on the wrong path. But he likes these stocks.

  • Warren Buffett scored 3,000% gains on this electric car maker way before the Rivian frenzy — here are 3 EV stocks still flying under Wall Street's radar

    The Oracle of Omaha turned millions into billions without relying on Tesla or Rivian.

  • Is this stock the next Amazon?

    Here's who this veteran Wall Street analyst thinks could be the next big tech investment.

  • With inflation at 30-year highs, these income stocks yielding as high as 10.2% can help you win the battle against soaring prices

    A carefully selected dividend stock portfolio can outrun inflation. 3 ideas to consider.

  • Market check: Bitcoin dips below $58K, stocks mixed

    Yahoo Finance's Jared Blikre breaks down the day's latest stock moves and cryptocurrency price action.

  • 2 Reasons Why fuboTV Stock Crashed After Earnings

    Instead, the issues arise from fuboTV's profit margins -- or lack thereof. It's losing money at a rapid rate and keeps raising capital that is diluting shareholders. Let's look closer at two reasons the market is concerned about fuboTV.

  • Chinese President Xi's e-commerce clampdown 'is not regulatory, it's personal,' analyst says

    John Freeman, CFRA Vice President of Equity Research, joins Yahoo Finance Live to break down Alibaba's earnings amid China's crackdown on tech and e-commerce companies.

  • CVS to Close About 900 Stores Over Three Years. Here Is Why.

    CVS Health is planning to close approximately 300 stores a year for the next three years, prompting the store to lower its end-of-year guidance. The store closures are a bid by CVS to restructure the company’s brick-and-mortar retail operations to adapt to changing consumer behavior, which favors retailers with effective digital channels as well as physical presence. “Investors are reacting positively to the entire new approach that CVS is taking which is, at its core, about making health services convenient and accessible in a consumer-friendly way,” said Jennifer Foster, Chilton Trust co-chief investment officer.

  • J.P. Morgan: These 2 “Strong Buy” Stocks Could Spike Over 60%

    The global economy’s emergence from the Covid-19 pandemic has coincided with altogether different challenges, amongst them the global supply chain issues. The lingering effect has impacted production, distribution and transportation and has led to shortages, longer waiting times for consumers and rising prices across the board. However, according to JPMorgan’s chief global markets strategist Marko Kolanovic there is a light at the end of the (congested) tunnel. “Global supply chain pressures are

  • Record selling by insiders is setting up stocks for a big fall, says contrarian investor

    Do the big company directors and insiders know something we don't? Our call of the day says look out below.

  • Is Teladoc Stock A Buy Or Sell Now? Here's What Fundamentals, TDOC Stock Chart Say

    According to MarketSmith, the number of mutual funds owning a piece of Teladoc stock has climbed steadily.